Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT01976507

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01976507
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01976507. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2016-12 (actual). Results posted on 2017-09-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Intervention (Drug)
dabigatran etexilate mesylate
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct01976507
Content hash
3eaf9f6b916f9c9d822e3334831ec10f9d5be58c03c7681983f75aa4abed2bf7